Maximum Resection and Immunotherapy Improve Glioblastoma Patient Survival: A Single-institution Prognostic Analysis

Eiichi Ishikawa (✉ e-ishikawa@md.tsukuba.ac.jp)
Faculty of Medicine, University of Tsukuba https://orcid.org/0000-0001-9224-9767

Narushi Sugii
Tsukuba Daigaku Igaku Iryokei

Masahide Matsuda
Tsukuba Daigaku Igaku Iryokei

Hidehiro Kohzuki
Tsukuba Daigaku Igaku Iryokei

Takao Tsurubuchi
Tsukuba Daigaku Igaku Iryokei

Hiroyoshi Akutsu
Tsukuba Daigaku Igaku Iryokei

Shingo Takano
Tsukuba Daigaku Igaku Iryokei

Akira Matsumura
Tsukuba Daigaku Igaku Iryokei

Research Article

Keywords: Tumor removal, glioma, intraoperative MRI, immunotherapy

DOI: https://doi.org/10.21203/rs.3.rs-387611/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Purpose. Glioblastoma (GBM) is a refractory disease with a poor prognosis and various methods, including maximum resection and immunotherapy, have been tested to improve outcomes. This retrospective study analyzed the prognostic factors of initially diagnosed glioblastoma patients at our institution to analyze the effect of these methods on prognosis.

Methods. Two hundred seventy-seven patients with initially diagnosed glioblastoma who were treated in our institution from 2009 to 2020. Various data, including extent of removal (EOR) and type of adjuvant therapy, were examined and prognostic relationships were analyzed.

Results. The median OS of the entire 277-case cohort, 200 non-biopsy cases, and 77 biopsy cases were 16.6 months, 19.7 months, and 9.7 months, respectively. Gross total removal (GTR; 100% of EOR) was achieved in 32.9% of the cases. Univariate analysis revealed younger age, right side, higher Karnofsky performance status, GTR, intraoperative MRI use for removal, proton therapy, combination immunotherapy, and discharge to home as good prognostic factors. Intraoperative MRI use and EOR were closely related. In the multivariate analysis, GTR, proton therapy, and combination of immunotherapies including autologous formalin-fixed tumor vaccine were the significant prognostic factors. A multivariate analysis of 91 GTR cases showed that immunotherapy contributed to prognostic improvements. The median OS and 5-year OS% values were 36.9 months and 43.3% in GTR cases receiving immunotherapy.

Conclusion. GTR, proton therapy, and immunotherapy were good prognostic factors in single-center GBM cases. Tumor vaccine therapy for GTR cases achieved a notably high median survival time and long-term survival ratio, indicating its usefulness in GTR cases.

Introduction

Glioblastoma (GBM) is generally a refractory disease with a poor prognosis for the majority of patients (1). Past papers have shown prognosis-related factors in glioblastoma patients receiving standard radiochemotherapy, such as extent of removal (2-4), patient age, isocitrate dehydrogenase (IDH) mutations, and methylation status of O6-methylguanine-DNA methyltransferase (MGMT) promotor among others (5-7). In addition, multiple immunotherapies for GBM patients have been conducted in an attempt to improve prognoses (8,9). Since January 2013, we have utilized intraoperative magnetic resonance imaging (MRI) to improve the extent of removal (10, 11), in addition to advanced treatments, including immunotherapy and proton therapy (12-15). In March 2013, we started a double-blinded, randomized phase IIb/III trial of autologous formalin-fixed tumor vaccine (AFTV) with standard chemotherapy and temozolomide (TMZ) for newly diagnosed GBM to evaluate the efficacy of AFTV for prevention of recurrence and/or cure of residual tumor burden (UMIN000010602) (13), and since October, 2020, GBM patients who had gross-total removal (GTR), resulting in no residual gadolinium enhancement, or subtotal removal (STR) are enrolled in a double-blinded, randomized phase III trial of AFTV. Similarly, in a double-blinded, randomized phase II trial of dendritic cell vaccine ICT-107, GBM patients who had undergone GTR, resulting in no residual gadolinium enhancement, or STR were enrolled. (16) In that study, progression-free survival (PFS) in the
intent-to-treat (ITT) population was significantly increased in the ICT-107 cohort by 2.2 months. In a phase 3 trial of an autologous tumor, featuring lysate-pulsed, dendritic cell vaccine (DCVax®-L) with standard therapy for newly diagnosed GBM, 63% of enrolled cases were GTR cases (17) and the median overall survival (mOS) of the overall ITT population (according to blinded interim data) was 23.1 months from the time of surgery. Moreover, various clinical methodologies, such combining immune checkpoint inhibitors to overcome relapse-mediating immunosuppressive mechanisms in the GBM microenvironment after monotherapy, are being tested (8, 18). However, no currently published paper has examined the superiority of immunotherapies in a phase III clinical study. The purpose of this study is thus to analyze the prognostic factors in consecutive cases of initially diagnosed glioblastoma in our institution for the past 11 years during the TMZ era and evaluate both the extent of removal and effect of these advanced treatments on GBM cases.

**Methods**

*Patient enrollment:*

A total of 277 patients with initially diagnosed glioblastoma who were treated in our institution from June 2009 to March 2020, including previous clinical trials at our institution, were registered in this retrospective study. Although TMZ was approved in Japan in September 2006, nimustine (ACNU) was widely used until May 2008 at our institution while many patients had unknown prognoses up through May 2009. Therefore, all patients until May 2009 at the same time of both ACNU and unknown prognosis patients were excluded. The study protocol was approved by the ethics committee of our institution (number R01-202). Various data, including patient age, sex, main location of the tumor, tumor side, Karnofsky Performance Status (KPS) of patients, extent of removal (EOR), interactive photodynamic diagnostic diagnosis (PDD) using 5-aminolevulinic acid (5-ALA), use of intraoperative MRI, IDH status, p53 status, MGMT status, type of radiotherapy, type of adjuvant therapy, and patient return at discharge were examined for relationships to the prognoses. As for EOR evaluated with T1-weighted-images after gadolinium administration on MRI within 3 days after surgery, GTR for complete disappearance of the contrast area (100% of EOR), STR for tumor volume reduction of 90% or more or tumor residuals with a maximum diameter of 10 mm or less, partial removal (PR) for 5% or more and less than 90%, and biopsy for less than 5% were set as fixed definitions. Information on the PDD fluorescence intensity was collected from surgical records and classified as strong, vague, or negative and those cases with positive fluorescence intensity but without any detailed descriptions were classified as positive.

*Intraoperative MRI system for tumor removal or biopsy and postoperative treatments*

Our intraoperative MRI system, the VISIUS® Surgical Theatre (IMRIS, Minnetonka, MN, USA), features both high-field (1.5T) ceiling-mounted and movable magnets, (10) to confirm the presence or absence of residual tumors for cases with maximum removal or to confirm accurate positioning for biopsy. Our institution uses the ceiling-mounted magnet to check for removal and the movable magnet for biopsy. For postoperative radiotherapy (RT), extended local radiation using 60 Gy (30 fraction) total irradiation dose or similar protocols were classified as 'conventional RT', RT using 45 Gy (15 fraction) or similar protocols
were ‘hypo-fractionated RT’, and RT using proton beams or combined with proton beams were classified as ‘proton therapy’. The critical inclusion criteria for this therapy were as follows: predicted radiation necrosis was unlikely to be fatal, the potential resectability of a lesion when brain necrosis was found in the 96.6 Gy irradiation range (15), and patients who accepted the advanced therapy after careful informed consent that fully explained possible complications. In addition, rare cases of whole brain radiotherapy (WBRT) were grouped separately. For postoperative adjuvant therapy, cases treated according to the modified Stupp regimen (RT concomitant with TMZ followed by TMZ maintenance therapy until recurrence or for 12 to 24 times) were classified into the ‘TMZ’ group. Cases using immunotherapy in addition to the modified Stupp regimen were classified into the ‘immunotherapy’ group. Of the 39 cases in the immunotherapy group at our institution, 31 cases received autologous formalin-fixed tumor vaccine (AFTV), the manufacturing method of which is described in the past paper of ours (12), 2 cases received interferon beta, and 6 cases received other drugs. Three of these cases with AFTV also received proton therapy. The critical inclusion criteria for the AFTV therapy were as follows: patients who underwent maximum possible resection (at least non-biopsy surgery) of the tumor, at least 1.5 g of neoplastic tissue for AFTV preparation was available (12), and patients who accepted the advanced therapy after careful informed consent that fully explained possible complications. Patients who started bevacizumab (BEV) before or concomitant with RT were classified into the ‘bevacizumab’ group. Our institution’s clinical protocol indicates that BEV treatment be used for low KPS patients receiving biopsy or PR surgery and most BEV cases also used TMZ.

**Detection of p53, MGMT and IDH statuses,**

For immuno-histochemistry (IHC) surveys of p53 and MGMT statuses, the corresponding staining indices were calculated as the average number of positive cells in the best-stained tumor areas with a total number of cells not less than 1000, as described previously (12). For category analyses, cases with 10% or more positive cells were rated as positive while cases with fewer than 10% positive cells were rated as negative for both MGMT and p53 (12). For p53 status, positive status, as determined by IHC in our institute, and mutation results from Sanger sequencing technique performed by Kansai Molecular Diagnosis Network for CNS tumors (KNBTG) in recent cases were grouped for analysis. In recent cases, MGMT status was also determined by methylation-specific polymerase chain reaction (PCR) or pyrosequencing in our institute, or quantitative methylation-specific PCR following the bisulfite modification of tumor genomic DNA performed by KNBTG. For IDH status, data results from Sanger sequencing by KNBTG for most of recent cases and IHC in our institute, using IDHR132H antibody, for the other cases ≥55 years old were grouped for analysis since the 2016 World Health Organization classification of brain tumors proscribes sequencing for IDH in GBM patients ≥55 years old.

**Statistical analysis**

For the analysis, χ2 test, Fisher’s exact test and logrank tests were used for univariate analyses and the Cox proportional hazard model was used for multivariate analysis with p <0.05 considered as significant. Statistical calculations were performed with IBP SPSS Statistics V25.0 software.
Results

Analysis for all 277 initially diagnosed GBM cases

Table 1 and Table 2 show various data for all 277 cases, including age; sex; location of main lesion; side of the lesion (right, left, other side [median, bilateral, multicentric]); KPS; EOR of the lesion; use of intraoperative PDD and fluorescence intensity; use of intraoperative MRI (for removal or for biopsy); IDH, p53, and MGMT promoter statuses of the lesion; type of RT; type of combination therapy; outcome at discharge (discharge to home, transfer to other facilities or dead during hospitalization); and their relationship to patient prognoses. The median OS of the entire 277-case cohort, the 200 non-biopsy cases, and the 77 biopsy cases were 16.6 months, 19.7 months, and 9.7 months, respectively with GTR (100% of EOR) achieved in 32.9% of the cases. Univariate analysis revealed that younger age, right side, higher KPS, GTR, intraoperative MRI use for removal, p53 status, proton therapy, combination immunotherapy, and discharge to home were good prognostic factors. Cases with IDH mutant status had longer OS (median OS was 28 months) than those with IDH wildtype (median OS was 15 months) and cases with MGMT methylated/negative status had longer OS (median OS was 21 months) than those with unmethylated/positive (median OS was 18 months), although no significant differences were seen.

Table 3 shows the results of a multivariate analysis regarding relation among OS and 7 factors (65-year-old or less, right side, KPS 70 or more, GTR, p53 negative/wild status, proton therapy, and immunotherapy groups). Intraoperative MRI use was excluded from multivariate analyses as a relating factor of EOR since they were closely related as shown in Fig1 indicates that only 40 (33.6%) out of 119 non-biopsy cases without intraoperative MRI resulted in GTR while 51 (63.0%) out of 81 non-biopsy cases with intraoperative MRI for removal were GTR (p=0.000, χ² test). In addition, return trips after discharge were also excluded as a confounding factor with patient’s prognosis itself and the type of radiotherapy (Conventional/Proton versus Others, p=0.000, Fisher’s exact test). In the multivariate analysis, GTR, proton therapy, and immunotherapy were the significant prognostic factors (Table3). Immunotherapy was more often selected for GTR cases than non-GTR cases (p=0.00, chi-square test) and any interactions between RT and EOR types (p>0.1, chi-square test) were not found. Figure 2 shows the survival curves comparing each favorable prognostic factor group with the other groups, visually confirming that cases in the GTR and immunotherapy groups show a tailed plateau curve, indicative of many long-term survivors. In the multivariate analysis regarding PFS, GTR (p=0.000, Exp=1.76) and immunotherapy (p=0.015, Exp=1.68) were the significant prognostic factors (detailed data not shown).

Sub-analysis regarding GTR and non-GTR cases

Table 4 shows the results of a multivariate analysis regarding relationship among OS and candidate factors of 91 GTR cases in order to extract those factors that contributed to the best prognosis in the GTR group. In this analysis, immunotherapy contributed to improvements in prognoses, while proton therapy did not contribute, despite no interaction between RT and EOR types (p>0.1, chi-square test). The PFS and OS curves for these factors in the GTR group are shown in Fig. 3. As shown in Fig. 3-B, the median OS was 36.9 months and the 5-year OS% was 43.3% in patients who underwent surgery resulting in GTR and
immunotherapy. Table 4 shows the results of a multivariate analysis regarding relationships between OS and candidate factors in 186 non-GTR cases. In this analysis, preoperative KPS and proton therapy, but not immunotherapy, contributed to improvements in prognoses.

Sub-analysis regarding AFTV cases

Table 5 shows the results of a multivariate analysis regarding relationship among OS and candidate factors search for good prognostic factors in 31 AFTV cases, which were the majority (79.5%) of the immunotherapy group. Here, only 3 cases (11%) out of 27 confirmed IDH statuses were IDH wildtype. The median OS of these 3 IDH mutant cases was 29.5 months. As for MGMT status, only 7 cases (28%) out of 25 confirmed status were methylated/negative status, others were unmethylated/positive status. Twenty cases resulted in GTR after surgery, 7 cases were STR, and 4 cases were PR. In this analysis, GTR was a good prognostic factor, in line with results seen in the analysis of the entire immunotherapy cohort. Figure 4 shows the PFS and OS curves for these factors in the AFTV group. Patients with AFTV had a median OS of 26.5 months and the GTR group had a notably good prognosis of 34.4 months for median OS and 40% for 5-year OS%.

Discussion

In this study, younger age, right side, higher KPS, GTR, intraoperative MRI use for removal, p53 status, proton therapy, combination immunotherapy, and discharge to home were good prognostic factors in the univariate analysis. Among these, GTR, proton therapy, and immunotherapy were extracted as good prognostic factors, while the use of intraoperative MRI was closely related to EOR. In previous reports, intraoperative MRI was observed to improve the removal rate (19, 20) and our current study is consistent with these reports. As for the right side resulting in a good prognosis in the univariate analysis, the requirement of complex informed consent for advanced therapies, including proton therapy and immunotherapy, may be involved. Informed consent that contained explanations of possible complications tended to include more non-aphasic patients (the majority of whom had right-side lesions) in these advanced therapies. For instance, 20 (61%) out of 33 patients who underwent proton therapy had right-sided lesions as did 24 (61%) out of 39 patients who received immunotherapy (detailed data not-shown).

In the sub-analysis, immunotherapy was a good prognostic factor in the GTR group while GTR was also a good prognostic factor in the AFTV group that happens to represent the majority of immunotherapy given in our institution. Our previous, prospective clinical studies have also shown that high EOR prolongs PFS and OS, although significant differences were only obtained in univariate analyses using the small number of patients that were enrolled in the study (12, 18). In the present study, however, the significance of this result seems to be high because of the large, albeit retrospective, amount of patient data (277 cases). Moreover, sub-analysis using GTR patient data (Fig3) shows immunotherapy can produce long survival (for up to 5 years) in approximately 40% of patients if the tumor lesion is surgically removed without any
residual bulk. To the best of our knowledge, no previous study has clarified this phenomenon. A recent meta-analysis using 9 total studies, representing 806 GBM patients, showed that half of GBM patients have PD-L1 overexpression and this expression in tumor tissues is significantly related to a poor OS (HR = 1.63, \( P = 0.003 \)) with heterogeneity (\( I^2 = 51\% \)) (21). This result indicates that tumor bulk in most GBM cases engenders resistance to cytotoxic T cell lymphocytes (CTLs), an idea bolstered by our previous studies that showed immunosuppressive PD-1-positive cells and M2 macrophages colocalized to GBM tissue in early relapse cases after AFTV (22, 23). We therefore speculate that vaccine therapies, including AFTV combined with immune checkpoint inhibitors, M2 macrophage inhibitors, or local therapy that provokes a local immune response, will prolong OS for both GTR and non-GTR cases. Combinations of immunotherapy based on this concept are expected to become the next generation of immunotherapy.

In this study, IDH status was not a statistically significant prognostic factor throughout the entire analysis (Table1) or in the 31 AFTV cases (detailed data not shown). The mOS values of IDH mutant GBM patients were fairly high (28.0 months in the entire analysis and 29.5 months in a sub-analysis using AFTV cases) and we speculate that this is due to the low number of IDH mutant cases. In a recent meta-analysis of GBM, 67 (36.61\%) of 183 IDH1 wild-type GBM cases were PD-L1-positive, while only one (3.85\%) of 26 IDH1 mutant GBM cases were PD-L1-positive. (21) The pooled OR indicates that PD-L1 positivity was closely related to IDH1 status (OR = 9.92, \( P = 0.007 \)),(21) revealing that CTLs in the GBM microenvironment are more effective in IDH1 mutant GBM. Future studies will accumulate the data to confirm this theory. In our study, p53-negative/wild type was a good prognostic factor in the univariate analysis of the entire dataset as shown in Table1 (mOS values were 19.1, 16.4, and 15.7 months in p53 negative/wildtype, p53 positive/mutant, and unexamined cases, respectively, \( p=0.047 \) by the logrank test). In this regard, p53 status had no effect on prognosis in the univariate analysis of 238 cases (excluding immunotherapy cases; median OS values were 15.9, 13.7, and 14.7 months in p53 negative/wildtype, p53 positive/mutant, and unexamined cases, respectively, \( p=0.162 \) by the logrank test) and we assumed that the immunotherapies improved the prognoses of p53 negative/wildtype GBM patients. Our previous studies also suggest that this type is a good prognostic factor in GBM patients who receive AFTV but future prospective studies are needed to verify this.

Limitations of this study must be acknowledged and, to address them, a multicenter, randomized Phase III trial on AFTV was begun to clarify immunotherapy benefits in GTR patients. Detailed information about MRI data including existence of contrast enhancement (CE) in the lesion, volume of CE area and volume of fluid-attenuated inversion recovery high-intensity area were not included in the analysis. Heterogeneity in type of testing for IDH, p53, and MGMT statuses might make the results inaccurate and our insufficient analysis of molecular markers of intratumoral tissues related to prognosis in the immunotherapy group, outside of these 3 markers, should be rectified by additional studies. In addition, as only 3 patients received immunotherapy combined with proton therapy, the effect of this combination cannot be clearly stated in this study.
In conclusion, GTR, proton therapy, and immunotherapy were good prognostic factors in the multivariate analysis of single-center GBM cases. Notably, tumor vaccine therapy for GTR cases achieved high median survival times and long-term survival ratios, revealing that vaccine therapy should be performed for GTR cases.

**Declarations**

**Availability of data and material**

The datasets generated during and/or analyzed during the current study are not publicly available since they include a few unpublished data from original clinical studies but are available from the corresponding author on reasonable request.

**Acknowledgment**

The authors deeply thank Tadao Ohno, Cell-Medicine, Inc. for their kind supervision regarding this study. The authors would additionally like to thank Dr. Alex Zaboronok in our department and Dr. Bryan J. Mathis of the University of Tsukuba Medical English Communications Center for language revision of this manuscript.

**Conflicts of Interest Disclosure**

The authors declare that no conflicts of interest exist in this study. This study was supported by a Grant-in-Aid for Scientific Research in Japan (Grant number: 18K08962).

**Author Contributions**

All authors contributed to the study conception and design. Material preparation, data collection was performed by Dr. EI and Dr. NS and analysis was performed by Dr. EI. The first draft of the manuscript was written by EI and the second draft was modified by EI, NS and MM. all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

**References**

1. Louis DN, Perry A, Reifenberger, G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. *Acta Neuropathol.* 2016, 131, 803–820
2. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001, 95(2): 190-8.
3. Li YM, Suki D, Hess K, Sawaya R. The influence of maximum safe resection of glioblastoma on survival in 1229 patients: Can we do better than gross-total resection? J Neurosurg. 2016, 124(4): 977-
4. Sanai N, Polley MY, McDermott MW, Parsa AT, Berger MS. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011, 115(1): 3-8.

5. Cohen AL, Colman H. Glioma biology and molecular markers. Cancer Treat Res. 2015, 163, 15–30.

6. Karsy, M. Neil JA, Guan J. Mahan MA., Colman H, Jensen RL A practical review of prognostic correlations of molecular biomarkers in glioblastoma. Neurosurg. Focus 2015, 38, E4.

7. Ludwig K. Kornblum Hl. Molecular markers in glioma. J. Neurooncol. 2017, 134, 505–512.

8. Miyazaki T, Ishikawa E, Sugii N, Matsuda M. Therapeutic Strategies for Overcoming Immunotherapy Resistance Mediated by Immunosuppressive Factors of the Glioblastoma Microenvironment. Cancers (Basel). 2020,12(7):1960.

9. Van Gool SW, Makalowski J, Fiore S, Sprenger T, Prix L, Schirrmacher V, Stuecker W. Randomized Controlled Immunotherapy Clinical Trials for GBM Challenged. Cancers (Basel). 2020, 13(1): 32.

10. Akutsu H, Yamamoto T, Masuda Y, Ishikawa E, Masumoto T, Matsuda M, Matsumura A. Movable intraoperative magnetic resonance imaging incorporating a seismic system. Clin Neurol Neurosurg. 2015, 135: 57-61.

11. Masuda Y, Akutsu H, Ishikawa E, Matsuda M, Masumoto T, Hiyama T, Yamamoto T, Kohzuki H, Takano S, Matsumura A. Evaluation of the extent of resection and detection of ischemic lesions with intraoperative MRI in glioma surgery: is intraoperative MRI superior to early postoperative MRI? J Neurosurg. 2018, 131(1): 209-216.

12. Ishikawa E, Muragaki Y, Yamamoto T, Maruyama T, Tsuboi K, Ikuta S, Hashimoto K, Uemae Y, Ishihara T, Matsuda M, Matsutani M, Karasawa K, Nakazato Y, Abe T, Ohno T, Matsumura A. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma. J Neurosurg. 2014,121(3): 543-53.

13. Ishikawa E, Yamamoto T, Matsumura A. Prospect of Immunotherapy for Glioblastoma: Tumor Vaccine, Immune Checkpoint Inhibitors and Combination Therapy. Neurol Med Chir (Tokyo). 2017, 57(7): 321-330.

14. Matsuda M, Kohzuki H, Ishikawa E, Yamamoto T, Akutsu H, Takano S, Mizumoto M, Tsuboi K, Matsumura A. Prognostic analysis of patients who underwent gross total resection of newly diagnosed glioblastoma. J Clin Neurosci. 2018, 50: 172-176.

15. Mizumoto M, Yamamoto T, Ishikawa E, Matsuda M, Takano S, Ishikawa H, Okumura T, Sakurai H, Matsumura A, Tsuboi K. Proton beam therapy with concurrent chemotherapy for glioblastoma multiforme: comparison of nimustine hydrochloride and temozolomide. J Neurooncol. 2016, 130(1): 165-170.

16. Wen PY, Reardon DA, Armstrong TS, Phuphanich S, Aiken RD, Landolfi JC, Curry WT, Zhu JJ, Glantz M, Peereboom DM, Markert JM, LaRocca R, O’Rourke DM, Fink K, Kim L, Gruber M, Lesser GJ, Pan E, Kesari S, Muzikansky A, Pinilla C, Santos RG, Yu JS. A randomized double-blind placebo-controlled phase II trial of dendritic cell vaccine ICT-107 in newly diagnosed patients with glioblastoma. Clin Cancer Res. 2019, 25(19): 5799-5807.
17. Rapp M, Grauer OM, Kamp M, Sevens N, Zotz N, Sabel M, Sorg RV. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial. 2018, 19(1): 293.

18. Ishikawa E, Yamamoto T, Matsumura A. Prospect of Immunotherapy for Glioblastoma: Tumor Vaccine, Immune Checkpoint Inhibitors and Combination Therapy. Neurol Med Chir (Tokyo). 2017, 57(7): 321-330.

19. Fukui A, Muragaki Y, Saito T, Maruyama T, Nitta M, Ikuta S, Kawamata T. Volumetric Analysis Using Low-Field Intraoperative magnetic resonance imaging for 168 newly diagnosed supratentorial glioblastomas: effects of extent of resection and residual tumor volume on survival and recurrence. World Neurosurg. 2017, 98: 73-80.

20. Roder C, Bisdas S, Ebner FH, Honegger J, Naegele T, Ernemann U, Tatagiba M. Maximizing the extent of resection and survival benefit of patients in glioblastoma surgery: high-field iMRI versus conventional and 5-ALA-assisted surgery. Eur J Surg Oncol. 2014, 40(3): 297-304.

21. Hao C, Chen G, Zhao H, Li Y, Chen J, Zhang H, Li S, Zhao Y, Chen F, Li W, Jiang WG. PD-L1 expression in glioblastoma, the clinical and prognostic significance: A systematic literature review and meta-analysis. Front Oncol. 2020, 24; 10: 1015.

22. Miyazaki T, Ishikawa E, Matsuda M, Akutsu H, Osuka S, Sakamoto N, Takano S, Yamamoto T, Tsuboi K, Matsumura A. Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome. J Neurooncol. 2017, 133(2): 277-285.

23. Miyazaki T, Ishikawa E, Matsuda M, Sugii N, Kohzuki H, Akutsu H, Sakamoto N, Takano S, Matsumura A. Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Ky inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells. Brain Tumor Pathol. 2020, 37(2): 41-49.

Tables

Table 1. Background and diagnostic factors in all 277 cases and their relationship to patient prognoses.
| Factors                  | Patient numbers | Median PFS (months) | P values | Median OS (months) | P values |
|--------------------------|-----------------|---------------------|----------|-------------------|----------|
| All cases                | 277             | 8.7                 |          | 16.6              |          |
| Age                      |                 |                     |          |                   |          |
| Median (percentile)      |                 |                     |          |                   |          |
| 66 or more               | 149             | (53.8%)             | 0.334    | 13.8              | 0.006    |
| 65 or less               | 128             | (46.2%)             | 9.4      |                   | 19.3     |
| Sex                      |                 |                     |          |                   |          |
| Men (%)                  | 165             | (59.6%)             | 0.281    | 16.6              | 0.966    |
| Women                    | 112             | (40.4%)             | 8.7      |                   | 15.7     |
| Main Location            |                 |                     |          |                   |          |
| Frontal                  | 104             | (37.5%)             | 0.395    | 16.2              | 0.179    |
| Temporal                 | 93              | (33.6%)             | 8.3      |                   | 15.1     |
| Parieto-Ocicipital       | 39              | (14.1%)             | 9.2      |                   | 24.8     |
| Others                   | 41              | (14.8%)             | 9.8      |                   | 15.7     |
| Side                     |                 |                     |          |                   |          |
| Right                    | 132             | (47.7%)             | 0.030    | 19.1              | 0.013    |
| Left                     | 118             | (42.6%)             | 8.2      |                   | 15.9     |
| Others                   | 27              | (9.7%)              | 5.1      |                   | 11.0     |
| KPS                      |                 |                     |          |                   |          |
| Median (percentile)      | 70              | (60-80)             |          |                   |          |
| 70 or more               | 190             | (68.6%)             | 0.190    | 19.7              | 0.006    |
| 60 or less               | 87              | (31.4%)             | 8.6      |                   | 11.2     |
| EOR                      |                 |                     |          |                   |          |
| Non-biopsy               | 200             | (72.2%)             |          | 19.7              |          |
| GTR (100% of EOR)        | 91              | (32.9%)             | 0.000    | 26.5              | 0.000    |
| STR                      | 58              | (20.9%)             | 9.2      |                   | 21.7     |
| PR                       | 51              | (18.4%)             | 5.3      |                   | 11.1     |
| Biopsy                   | 77              | (27.8%)             | 7.1      |                   | 9.7      |
| 5-ALA                    |                 |                     |          |                   |          |
| Strong                   | 190             | (68.6%)             | 0.096    | 16.8              | 0.300    |
| Vague                    | 31              | (11.2%)             |          | 14.4              |          |
| Positive                 | 11              | (4.0%)              | 11.5     |                   | 18.0     |
| Intraoperative MRI | Yes (for removal) | 82 (29.6%) | 11.2 | 0.009 | 21.7 | 0.000 |
|--------------------|-------------------|------------|------|--------|------|--------|
|                    | Yes (for biopsy)  | 12 (4.3%)  | 6.4  |        |      |        |
|                    | Not used          | 183 (66.1%)| 8.1  |        |      | 14.7   |

| IDH               | Mutant            | 17 (6.1%)  | 14.6 | 0.365 | 28.0 | 0.256 |
|-------------------|-------------------|------------|------|--------|------|--------|
|                   | Wild              | 197 (71.1%)| 8.6  |        |      | 14.5   |
|                   | Not examined      | 63 (22.7%) | 8.4  |        |      | 21.6   |
| p53               | Positive/Mutant   | 109 (39.4%)| 8.3  | 0.307 | 16.4 | 0.047 |
|                   | Negative/Wild     | 129 (46.6%)| 9.7  |        |      | 19.1   |
|                   | Not examined      | 39 (14.1%) | 8.2  |        |      | 15.7   |
| MGMT              | Negative/Methylated| 44 (15.9%) | 11.2 | 0.451 | 21.4 | 0.267 |
|                   | Positive/Unmethylated| 117 (42.2%)| 7.9  |        |      | 18.1   |
|                   | Not examined      | 116 (41.9%)| 8.9  |        |      | 15.1   |

**Table 2** Radiation therapy, combination therapies, and discharge destination outcomes for all 277 cases and their relationship to patient prognoses.
Table 3. A multivariate analysis of 7 factors from all 277 patient data and their relationship to patient prognoses (OS).

| Factors | Patient numbers | Median PFS (months) | P values | Median OS (months) | P values |
|---------|----------------|---------------------|----------|-------------------|----------|
| All cases | 277 | 8.7 | 16.6 |        |          |
| RT | | | | | |
| Conventional | 195 (70.4%) | 9.0 | 0.000 | 17.7 | 0.000 |
| Hypofractionation | 41 (14.8%) | 7.3 | 8.6 | | |
| WBRT | 5 (1.8%) | 5.5 | 8.1 | | |
| Proton | 33 (11.9%) | 11.3 | 28.7 | | |
| Not used | 3 (1.1%) | 2.8 | 2.8 | | |
| Combination therapies | | | | | |
| TMZ | 180 (65%) | 8.6 | 0.001 | 17.0 | 0.000 |
| TMZ + BEV | 43 (15.5%) | 8.7 | 11.0 | | |
| TMZ + Immunotherapy | 39 (14.1%) | 12.5 | 29.5 | | |
| Others | 15 (5.4%) | 5.5 | 10.2 | | |
| Place after Discharge | | | | | |
| Home | 144 (52.0%) | 10.5 | 0.000 | 23.5 | 0.000 |
| Trans | 130 (46.9%) | 7.1 | 10.8 | | |
| Death during hospitalization | 3 (1.1%) | 2.7 | 2.7 | | |
| Factors         | Groups                                | P values | Exp (95%CI) |
|-----------------|---------------------------------------|----------|-------------|
| Age             | 65 or less versus others              | 0.466    |             |
| Side            | Right versus others                   | 0.449    |             |
| pre KPS         | 70 or more versus others              | 0.093    |             |
| EOR             | GTR versus others                     | 0.000    | 2.14 (1.57-2.92) |
| p53             | Negative/wild versus others           | 0.108    |             |
| RT              | Proton therapy versus others          | 0.025    | 1.60 (1.06-2.40) |
| Combination therapy | Immunotherapy versus others       | 0.003    | 1.89 (1.23-2.88) |

**Table 4.** A multivariate analysis of age, KPS and 2 candidate factors (RT, Adjuvant therapy) in 91 GTR cases and their relationship to patient prognoses (OS), and a multivariate analysis in 186 non-GTR cases and their relationships to patient prognoses (OS).

| Factors         | Groups                                | P values | Exp (95%CI) |
|-----------------|---------------------------------------|----------|-------------|
| GTR cases       | Age 65 or less versus others          | 0.336    |             |
|                 | pre KPS 70 or more versus others      | 0.414    |             |
|                 | RT Proton therapy versus others       | 0.397    |             |
|                 | Adjuvant Immunotherapy versus others  | 0.006    | 2.35 (1.27-4.33) |
| Non-GTR cases   | Age 65 or less versus others          | 0.802    |             |
|                 | pre KPS 70 or more versus others      | 0.016    | 1.541 (1.083-2.192) |
|                 | RT Proton therapy versus others       | 0.023    | 1.948 (1.094-3.469) |
|                 | Adjuvant Immunotherapy versus others  | 0.135    |             |

**Table 5.** A multivariate analysis of age, KPS and 2 candidate factors in 31 AFTV cases and their relationship to patient prognoses (OS).
| Factors | Groups                      | P values | Exp (95% CI)     |
|---------|-----------------------------|----------|------------------|
| Age     | 65 or less versus others    | 0.120    |                  |
| pre KPS | 70 or more versus others    | 0.471    |                  |
| EOR     | GTR versus others           | 0.005    | 3.64 (1.48-8.93) |
| RT      | Proton therapy versus others| 0.780    |                  |

**Figures**

![Figure 1](image)

**Figure 1**
Extent of resection (EOR) of initially diagnosed glioblastoma (GBM) in tumor removal (non-biopsy) cases without intraoperative MRI and with intraoperative MRI.

Figure 2

The overall survival (OS) curve for the entire 277 GBM cohort (A) and this curve divided by EOR consisting of gross total removal (GTR), subtotal removal (STR), partial removal (PR) and biopsy (B); type of radiotherapies (RT), including proton therapy, conventional RT, hypofractionated RT (Hypofraction), whole brain RT (WBRT), and no RT (non) (C); and type of combination therapy including temozolomide (TMZ) + immunotherapy (IMT), TMZ, Bevacizumab (BEV) with or without TMZ, and others (D).
Figure 3

The progression-free survival (PFS) (A) and OS (B) curves for 91 cases with GTR (left) and each curve of the cases divided by type of combination therapy consisting of TMZ+ IMT, TMZ, BEV with or without TMZ, and others (right). The logrank test is used for analysis.
Figure 4

The PFS (A) and OS (B) curves for 31 cases with AFTV immunotherapy (left) and each curve of the cases divided by EOR consisting of GTR, STR, and PR (right). The logrank test is used for analysis.